156792-21-1

Basic information

• Product Name: (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester
• Synonyms: (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester
• CAS NO: 156792-21-1
• Molecular Weight: 411.587
• Mol File: 156792-21-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester(156792-21-1)
• EPA Substance Registry System: (S)-2-((S)-2-Acetylsulfanylmethyl-4-phenyl-butyrylamino)-4-methylsulfanyl-butyric acid ethyl ester(156792-21-1)

Safety Data

• Hazardous Substances Data: 156792-21-1(Hazardous Substances Data)

Upstream product

• 2899-36-7 L-methionine ethyl ester monohydrochloride 
• 116112-44-8 2-[(acetylthio)methyl]-4-phenylbutanoic acid 
• 156757-40-3 1,1-dimethylethyl α-<((R,S)-acetylthio)methyl>benzenebutanoate 
• 89074-52-2 1,1-dimethylethyl 2-(2-phenylethyl)-3-oxobutanoate 
• 84793-30-6 1,1-dimethylethyl α-methylenebenzenebutanoate 
• 103-63-9 1-phenyl-2-bromoethane 

Relevant articles and documents

Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure- activity relationship studies of methionine and S-alkylcysteine derivatives

A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C- terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2- methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.